Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial ; volume:30 ; number:1 ; day:5 ; month:12 ; year:2023 ; pages:271-278 ; date:1.2024
Nature medicine ; 30, Heft 1 (5.12.2023), 271-278, 1.2024

Creator
Desai, Jayesh
Alonso, Guzman
Kim, Se Hyun
Cervantes, Andres
Karasic, Thomas
Medina, Laura
Shacham-Shmueli, Einat
Cosman, Rasha
Falcon, Alejandro
Gort, Eelke
Guren, Tormod
Massarelli, Erminia
Miller, Wilson H.
Paz-Ares, Luis
Prenen, Hans
Amatu, Alessio
Cremolini, Chiara
Kim, Tae Won
Moreno, Victor
Ou, Sai-Hong
Passardi, Alessandro
Sacher, Adrian
Santoro, Armando
Stec, Rafal
Ulahannan, Susanna
Arbour, Kathryn
Lorusso, Patricia
Luo, Jia
Patel, Manish R.
Choi, Yoonha
Shi, Zhen
Mandlekar, Sandhya
Lin, Mark T.
Royer-Joo, Stephanie
Chang, Julie
Jun, Tomi
Dharia, Neekesh V.
Schutzman, Jennifer L.
Han, Sae-Won
Contributor
SpringerLink (Online service)

DOI
10.1038/s41591-023-02696-8
URN
urn:nbn:de:101:1-2024040122330805854412
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:45 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Desai, Jayesh
  • Alonso, Guzman
  • Kim, Se Hyun
  • Cervantes, Andres
  • Karasic, Thomas
  • Medina, Laura
  • Shacham-Shmueli, Einat
  • Cosman, Rasha
  • Falcon, Alejandro
  • Gort, Eelke
  • Guren, Tormod
  • Massarelli, Erminia
  • Miller, Wilson H.
  • Paz-Ares, Luis
  • Prenen, Hans
  • Amatu, Alessio
  • Cremolini, Chiara
  • Kim, Tae Won
  • Moreno, Victor
  • Ou, Sai-Hong
  • Passardi, Alessandro
  • Sacher, Adrian
  • Santoro, Armando
  • Stec, Rafal
  • Ulahannan, Susanna
  • Arbour, Kathryn
  • Lorusso, Patricia
  • Luo, Jia
  • Patel, Manish R.
  • Choi, Yoonha
  • Shi, Zhen
  • Mandlekar, Sandhya
  • Lin, Mark T.
  • Royer-Joo, Stephanie
  • Chang, Julie
  • Jun, Tomi
  • Dharia, Neekesh V.
  • Schutzman, Jennifer L.
  • Han, Sae-Won
  • SpringerLink (Online service)

Other Objects (12)

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab

Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts

Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts

Colorectal cancer with KRAS mutation

Colorectal cancer with KRAS mutation

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

Related objects